Recursion Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of unusually large options trading on Thursday. Stock investors purchased 52,856 call options on the company. This is an increase of 134% compared to the typical volume of 22,543 call options.

Recursion Pharmaceuticals Trading Up 6.8%

RXRX opened at $4.85 on Friday. Recursion Pharmaceuticals has a 52 week low of $3.79 and a 52 week high of $12.36. The business has a fifty day simple moving average of $5.35 and a 200-day simple moving average of $5.35. The firm has a market cap of $2.11 billion, a P/E ratio of -2.72 and a beta of 0.91. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $19.10 million for the quarter, compared to analysts’ expectations of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The company’s quarterly revenue was up 33.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.40) earnings per share. On average, equities analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Insider Activity

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the completion of the sale, the insider directly owned 668,197 shares of the company’s stock, valued at $3,688,447.44. The trade was a 5.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 8.43% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of RXRX. Centaurus Financial Inc. increased its position in Recursion Pharmaceuticals by 32.0% in the 2nd quarter. Centaurus Financial Inc. now owns 14,665 shares of the company’s stock valued at $74,000 after acquiring an additional 3,555 shares during the period. Liontrust Investment Partners LLP increased its holdings in shares of Recursion Pharmaceuticals by 18.0% during the 2nd quarter. Liontrust Investment Partners LLP now owns 702,386 shares of the company’s stock worth $3,554,000 after buying an additional 107,331 shares during the last quarter. Hudson Bay Capital Management LP increased its holdings in shares of Recursion Pharmaceuticals by 18.0% during the 2nd quarter. Hudson Bay Capital Management LP now owns 150,000 shares of the company’s stock worth $759,000 after buying an additional 22,930 shares during the last quarter. Headlands Technologies LLC boosted its position in Recursion Pharmaceuticals by 20.2% during the 2nd quarter. Headlands Technologies LLC now owns 199,415 shares of the company’s stock worth $1,009,000 after purchasing an additional 33,565 shares during the period. Finally, Sender Co & Partners Inc. purchased a new position in Recursion Pharmaceuticals in the 2nd quarter valued at about $121,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 target price for the company. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $7.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.